Psoriasis Clinical Trials in San Diego

View 28 new treatments for Psoriasis in San Diego, CA, and other areas near me, such as Carlsbad, Chula Vista, El Cajon, Escondido, Oceanside and Vista. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.
View 29 trials in San Diego
Filter (29)

Deucravacitinib for Psoriasis

Bristol-Myers Squibb Clinic, San Diego + 2 more

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Waitlist
Phase 4
Est. 6 - 12 Weeks
Bristol-Myers Squibb
Study Director

Risankizumab vs Deucravacitinib for Psoriasis

AbbVie Clinic, San Diego + 1 more

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen). In participants with psoriasis, certain skin cells multiply much faster and the skin can develop rough patches that may be red or white with scales. There are many types of psoriasis, but plaque psoriasis is the most common. The exact cause of psoriasis is unknown, but researchers think it may be caused by the body's immune system not working properly. This study is designed to enroll 336 participants 18 years of age and older with have been diagnosed with moderate chronic plaque psoriasis for at least 6 months prior to Baseline (Day 1) and who have not previously been treated with a biologic treatment (natural substance that is made by using living cells in a laboratory). This is a Phase 4, randomized, open-label, assessor blinded, active comparator study with 2 Parts. Phase 4 studies test treatments that have already been approved to treat patients with a condition or disease. This study is open-label, which means that both participants and study doctors know which study treatment is given to participants Participants will be administered subcutaneous (SC) treatment of risankizumab every 12 weeks for up to 44 weeks or provided deucravacitinib oral tablets to be taken once daily. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 6 Weeks
ABBVIE INC.
Study Director

Brodalumab for Pediatric Psoriasis

Bausch Clinic, San Diego + 1 more

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 12 Weeks
Varsha Bhatt
Study Director

Bimekizumab for Psoriatic Arthritis

UCB Biopharma Clinic, San Diego + 1 more

This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
UCB Cares
Study Director

ESK-001 for Psoriasis

Alumis Clinic, Encinitas + 3 more

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Apremilast for Pediatric Plaque Psoriasis

Amgen Clinic, San Diego + 1 more

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
MD
Study Director

Risankizumab for Psoriatic Arthritis

AbbVie Clinic, San Diego + 1 more

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
ABBVIE INC.
Study Director

JNJ-77242113 for Plaque Psoriasis

Janssen Clinic, Oceanside + 2 more

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Janssen Research & Development, LLC Clinicaltrial
Study Director

Deucravacitinib for Psoriasis

Bristol-Myers Squibb Clinic, San Diego + 4 more

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director

JNJ-77242113 for Plaque Psoriasis

Janssen Clinic, San Diego + 1 more

This trial is testing a new medication called JNJ-77242113 to see if it helps people with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches. The study aims to find out if this new treatment can improve symptoms for those who have not responded well to other treatments.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Page 1 of 3

Frequently Asked Questions

How much do psoriasis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do psoriasis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across psoriasis trials in San Diego, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for psoriasis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in San Diego is research being conducted for psoriasis?

In San Diego, clinical trials for psoriasis are being conducted at Therapeutics Clinical Research and MedDerm Associates. These trials are primarily located in the central and northern parts of the city, with approximately 12 trials ongoing as of 2024.

What promising new drugs are being tested?

In San Diego, psoriasis research is focusing on treatments like Monoclonal Antibodies and TNF-alpha Inhibitors. Notable drugs being studied include Guselkumab, Bimekizumab, and Etanercept.